BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to fight age-related degenerative diseases, announces today the implementation of a €10 million bond financing with Kreos Capital.
Stanislas Veillet, CEO of BIOPHYTIS, stated: “This transaction allows us to fund the development of BIOPHYTIS Inc (Cambridge, MA) where we are currently recruiting the team to oversee the clinical and regulatory development of our drug candidates in the US. In particular the SARA phase 2b program in sarcopenia which already comprises 5 centers open in the US. This funding also contributes to the preparation of the MYODA clinical program in Duchenne myopathy, which is expected to be authorized by the FDA before the end of 2018.”
